Given that current DCexo studies are focusing on peptide- or protein-loaded DCexos from conventional DCs (cDCs) [26,99], there is a critical need to expand our studies with new approaches to generate DCexos capable of priming CD8 T cells in vivo, and elucidate the underlying mechanisms of their functions in generating anti-tumor immunity (Table 1). This evidence concerns the gene CD8A and neoplasm.